The goal of the study was to ascertain whether GI adverse events (GI AEs), such as nausea/vomiting, diarrhea, constipation, and dyspepsia (indigestion), during the dose escalation phase (baseline to week 12) and from baseline to the end of treatment, are responsible for the greater weight loss seen with semaglutide compared to other GLP-1RAs
Sunday evening: Copper peptide focus
Long-term levodopa treatment, while effective in alleviating motor symptoms, has been associated with increased oxidative stress and the generation of toxic metabolites, which can accelerate the loss of dopaminergic neurons
Long term side effects, however, are possible
(2014) showed in a mouse model that hydroxytyrosol prevented diet-induced obesity, hyperglycaemia, and insulin resistance over a 17-week supplementation period, with effects on fasting glucose comparable to metformin